| Company Name | Novo Nordisk Pharma (Taiwan) Ltd. |
|---|---|
| Protocol Number | NN8022-7780 |
| Title of Study | Multicentre, single-arm, non-interventional regulatory post-marketing surveillance (rPMS) study to evaluate the safety and effectiveness of Saxenda® for weight management in routine clinical practice in Taiwan |
| Primary Objective | To investigate the safety profile (AE) of Saxenda® for weight management in clinical use for adults and adolescents in Taiwan. |
| Number of Sites | 13 |
| Period of Study | From：2024/02 to：2025/08 |
| Number of Patients | 288人 |
| IRB Approval Date | National Taiwan University Hospital Feb-2024 China Medical University Hospital Feb-2024 Linkou Chang-Gung Memorial Hospital Feb-2024 Chia-Yi Christian Hospital Jan-2024 Changhua Christian Hospital Feb-2024 Kaohsiung Medical University Hospital Feb-2024 Tungs' Taichung MetroHarbor Hospital Feb-2024 Kuang Tien General Hospital Feb-2024 Taipei University Hospital Feb-2024 Genesis Clinic Feb-2024 TZ Clinic Feb-2024 Hsinchu Mackay Memorial Hospital Feb-2024 Hsinchu Municiple Mackay Childen's Hospital Mar-2024 |
| Publication Plan / Date | 2026 |
